William Blair & Company
SGMO

William Blair & Company’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

William Blair & Company’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,000
Closed -$6.73K – 1937
2025
Q3 		$6.73K Hold
10,000
– – ﹤0.01% 1781
2025
Q2 		$5.41K Sell
10,000
-500
-5% -$297 ﹤0.01% 1760
2025
Q1 		$6.89K Hold
10,500
– – ﹤0.01% 1737
2024
Q4 		$10.7K Sell
10,500
-40,000
-79% -$73.1K ﹤0.01% 1732
2024
Q3 		$43.7K Sell
50,500
-9,402
-16% -$6.89K ﹤0.01% 1647
2024
Q2 		$21.5K Sell
59,902
-65,000
-52% -$35.1K ﹤0.01% 1682
2024
Q1 		$83.7K Hold
124,902
– – ﹤0.01% 1534
2023
Q4 		$67.9K Sell
124,902
-150,000
-55% -$69.2K ﹤0.01% 1556
2023
Q3 		$165K Sell
274,902
-20,000
-7% -$21.4K ﹤0.01% 1427
2023
Q2 		$383K Hold
294,902
– – ﹤0.01% 1152
2023
Q1 		$519K Hold
294,902
– – ﹤0.01% 1034
2022
Q4 		$926K Sell
294,902
-50,000
-14% -$194K ﹤0.01% 846
2022
Q3 		$1.69M Hold
344,902
– – 0.01% 659
2022
Q2 		$1.43M Hold
344,902
– – 0.01% 730
2022
Q1 		$2M Hold
344,902
– – 0.01% 696
2021
Q4 		$2.59M Buy
+344,902
New +$3M 0.01% 649
2017
Q3 		– Sell
-12,100
Closed -$106K – 1490
2017
Q2 		$106K Buy
12,100
+500
+4% +$3.21K ﹤0.01% 1422
2017
Q1 		$60K Hold
11,600
– – ﹤0.01% 1323
2016
Q4 		$35K Buy
11,600
+300
+3% +$1.09K ﹤0.01% 1272
2016
Q3 		$52K Buy
11,300
+900
+9% +$4.58K ﹤0.01% 1253
2016
Q2 		$60K Sell
10,400
-5,500
-35% -$35.1K ﹤0.01% 1193
2016
Q1 		$96K Sell
15,900
-5,500
-26% -$33K ﹤0.01% 1126
2015
Q4 		$195K Buy
+21,400
New +$165K ﹤0.01% 1092

Other funds holding SGMO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

William Blair & Company's SGMO Position: Q4 2025 in Review

William Blair & Company sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2025, closing a stake of 10,000 shares — an estimated $6.73K sold.

William Blair & Company first reported a position in SGMO in Q4 2015 and held it in 23 quarters. The position peaked at $2.59M in Q4 2021. 105 funds tracked by Wall St. Rank hold SGMO as of Q4 2025.

  • William Blair & Company reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2025 after selling out during the quarter.
  • William Blair & Company sold 10,000 SANGAMO THERAPEUTICS INC shares in Q4 2025, an estimated $6.73K.
  • William Blair & Company first reported a position in SANGAMO THERAPEUTICS INC in Q4 2015 and held it in 23 quarters.
  • William Blair & Company's SANGAMO THERAPEUTICS INC position peaked at $2.59M in Q4 2021.
  • 105 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2025.

Based on William Blair & Company's 13F filing for Q4 2025, filed 17 Feb 2026.